How ChondroFiller works in the hip joint

Think of ChondroFiller™ as a temporary framework placed inside the hip joint — not a lubricant and not a filler, but a biological scaffold that gives the body a structure to build repair tissue around. Technically it is a CE-marked Class III acellular Type I collagen hydrogel, but in practical terms it behaves like a precision-shaped sponge: injected as a liquid under ultrasound guidance, it gels within 3–5 minutes once inside the joint, conforming to the shape of the cartilage defect rather than dispersing through joint fluid.

The active process that follows is called acellular matrix-induced chondrogenesis — meaning the scaffold (not injected cells) draws the patient's own progenitor cells in from the surrounding synovium and subchondral bone. Those cells progressively lay down repair tissue within the scaffold's structure. Over roughly 6–24 months the collagen matrix itself resorbs; the repair tissue it stimulated continues to mature after the scaffold has gone.

This distinguishes ChondroFiller™ clearly from hyaluronic acid injections, which lubricate and cushion but provide no structural scaffold or regenerative stimulus, and from corticosteroid, which reduces inflammation without any structural effect. Where ChondroFiller™ appears alongside other injections in a treatment plan, it is the regenerative component.

The entire delivery is an outpatient injection under local anaesthesia, guided by real-time ultrasound — no surgical incision and no general anaesthetic.

Whether ChondroFiller suits your hip

Suitability comes down to three things: the nature of the cartilage damage, the overall condition of the hip joint, and whether the background level of osteoarthritis is mild enough for regenerative treatment to take hold.

The strongest evidence applies to patients with a focal, full-thickness cartilage defect larger than 2 cm² — typically on the acetabular surface, often linked to femoroacetabular impingement (FAI). In the Mazek 2021 cohort of 26 adults meeting these criteria, 81% achieved good or excellent MRI-confirmed repair at five years. Those patients still had preserved joint space, no significant bone loss, and minimal background osteoarthritis.

That last point matters. Osteoarthritis severity is graded on the Tönnis scale — a simple 0–3 measure of joint-space narrowing and bony change on X-ray, where 0 means no arthritic change and 3 means advanced degeneration. ChondroFiller is suited to Tönnis 0 or 1 hips. In the same dataset, patients with Tönnis 2 or 3 had poor outcomes, so advanced or widespread hip osteoarthritis places a patient outside the indicated range.

ChondroFiller is not appropriate for generalised hip OA, heavily degenerated joints, or cases where significant structural problems — such as uncorrected malalignment — remain unaddressed.

One practical point worth noting early: ChondroFiller is a self-funded private treatment in the UK. There is currently no NHS pathway and no PMI reimbursement route.

Confirming suitability requires a pre-procedure MRI to map the defect accurately — both its size and depth — before any appointment is finalised.

What happens at your outpatient appointment

On the day of the appointment, no hospital bed is booked and no theatre slot is needed. The ChondroFiller injection is carried out in a clinical room under local anaesthesia, and most patients leave the same afternoon.

Before the injection

The appointment begins with a short consultation to review your MRI, confirm the defect location, and check that nothing has changed since your pre-procedure imaging. This is also the moment to ask any last questions about what follows.

During the injection

The clinician uses a real-time ultrasound probe to map the hip before and throughout the procedure — and this step matters more for the hip than for almost any other joint. The anterior hip joint space sits 4–8 cm beneath the skin surface, with the femoral artery approximately 1.9 cm medial to the capsule, the femoral vein about 1.7 cm medial, and the femoral nerve roughly 2.3 cm lateral. With those structures in such close proximity, accurate needle placement is a safety requirement, not a refinement. A 2016 systematic review by Hoeber and colleagues quantified the difference: landmark-guided hip injections achieved accurate intra-articular placement in around 72% of attempts, whilst image-guided techniques reached 100% — a statistically significant gap (p<0.0001).

Once the needle tip is confirmed inside the hip joint under live ultrasound, the ChondroFiller liquid is delivered precisely into the defect, where it gels in place within minutes. Intravenous antibiotic prophylaxis is given at the time of the procedure as a precautionary standard.

After the injection

You will rest briefly before being discharged with written advice on weight-bearing and what to expect over the following weeks. No overnight stay is required.

Recovery and return to activity after your injection

Recovery begins the moment you leave the clinic, and the first six weeks are the most constrained.

0–6 weeks: protecting the scaffold

For approximately the first six weeks, partial weight-bearing is the norm — most patients need crutches or a walking aid to keep load off the hip whilst the collagen scaffold integrates into the defect. This is not an optional precaution; the gel requires time to anchor properly before meaningful loading can occur. Gentle, non-impact movement is generally encouraged throughout this period to maintain joint mobility without stressing the repair site.

Six-week review

The six-week appointment is the key clinical checkpoint. Imaging or clinical assessment at that visit guides what comes next — progressive loading and low-impact activity are typically introduced only once the clinician is satisfied with early integration. Swimming and stationary cycling are usually among the first activities reintroduced, alongside walking on even ground. Individual physiotherapy guidance will be provided at this review rather than in advance, because progression depends on how each hip has responded.

6–12 months and beyond

High-impact activities and sport are not expected before around 12 months post-injection. The biological repair process ChondroFiller initiates — acellular matrix-induced chondrogenesis — matures over months, not weeks, and the absence of early dramatic pain relief does not indicate failure. In the Mazek 2021 cohort, MRI-confirmed cartilage healing was evaluated at three, four, and five years, and functional scores continued to rise across that entire window: the twelve-month mark is a meaningful progress point, but not the endpoint of repair.

What the clinical evidence shows

The most direct measure of functional change comes from the Harris Hip Score data: across published ChondroFiller hip studies, patients gained an average of approximately 33 points — a shift large enough to move many individuals from symptomatic restriction into near-normal function. The Mazek 2021 cohort underpins this figure: 26 adults with focal acetabular defects exceeding 2 cm², followed for between one and five years, with MRI used to confirm the degree of cartilage repair at each interval. Eighty-one per cent of evaluable patients reached a good or excellent rating at three, four, and five years — consistent rather than declining, which matters when assessing durability.

Beyond that cohort, a 2023 ultrasound-guided collagen injection study in 44 patients with early hip osteoarthritis (Kellgren-Lawrence Grade I–II) reported statistically significant improvement in both VAS pain scores (p<0.0001) and total WOMAC scores (p<0.0001) with no adverse events recorded across the trial period. The complaint rate for ChondroFiller across published data sits at approximately 0.06%.

What the evidence cannot yet tell us

The Mazek cohort is 26 patients — a prospective series, not a large randomised controlled trial. Five years is the longest follow-up horizon currently available for the injection route in the hip; whether outcomes hold at ten years is not yet known. Optimal dosing volume for ultrasound-guided delivery specifically has not been formally standardised in published guidance. The best available hip data support cautious optimism, not certainty.

Booking a ChondroFiller assessment at Lincolnshire Hip

Appointments at Lincolnshire Hip's clinics in Sleaford and Grantham are open to patients across Lincolnshire and the wider non-London UK catchment — no GP referral is required to book.

An MRI of the hip is typically needed before the procedure can be planned. If you do not have recent imaging, the team can advise on arranging it before your assessment visit. The appointment is where candidacy is confirmed rather than assumed: the scan findings are reviewed against the focal-defect and Tönnis-grade criteria discussed in this article, and a clinical decision on suitability is usually reached on the same day.

ChondroFiller injection is self-funded private treatment — ask about current guide costs when booking, as no NHS or private medical insurance pathway currently exists. Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment.

If the MRI confirms a focal, well-contained defect in a hip with mild background OA, the assessment visit is where that finding becomes a clear treatment plan — or, equally, where an alternative pathway is identified if ChondroFiller is not the right fit.

1. [1] Ultrasound guided injection with Collagen-based Medical Device: real-life evaluation of efficacy and safety in hip osteoarthritis. (2023). https://doi.org/10.11152/mu-4242 https://doi.org/10.11152/mu-4242
2. [2] Hip Arthroscopy and Chondrofiller Application in Isolated Osteochondral Defect of the Femoral Head. (2025). https://doi.org/10.13107/jocr.2025.v15.i10.6176 https://doi.org/10.13107/jocr.2025.v15.i10.6176
3. [3] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002